CU20250022A7 - Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral - Google Patents

Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral

Info

Publication number
CU20250022A7
CU20250022A7 CU2025000022A CU20250022A CU20250022A7 CU 20250022 A7 CU20250022 A7 CU 20250022A7 CU 2025000022 A CU2025000022 A CU 2025000022A CU 20250022 A CU20250022 A CU 20250022A CU 20250022 A7 CU20250022 A7 CU 20250022A7
Authority
CU
Cuba
Prior art keywords
bispecific antibody
tumor antigen
binds specifically
treating diseases
disorders mediated
Prior art date
Application number
CU2025000022A
Other languages
English (en)
Inventor
Alina Valerevna Beliasnikova
Valentina Yurevna Filina
Anastasiya Andreevna Ivanova
Segei Mikhailovich Krat
Olga Leonidovna Kytmanova
Sergei Aleksandrovich Legotskll
Dmitry Valentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2023105614A external-priority patent/RU2023105614A/ru
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of CU20250022A7 publication Critical patent/CU20250022A7/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

<p>La presente invención se refiere al campo de la biotecnología y la medicina, en particular a un anticuerpo biespecífico que se une específicamente al CD3 y a un antígeno tumoral. La invención se refiere además a un ácido nucleico que codifica el anticuerpo biespecífico sujeto, un vector de expresión, una célula huésped para producir el anticuerpo biespecífico sujeto y un método para producir dicha célula, composiciones farmacéuticas que comprenden el anticuerpo biespecífico según la invención, y otros compuestos terapéuticamente activos, métodos para tratar enfermedades o trastornos mediados por un antígeno tumoral, uso del anticuerpo biespecífico o composiciones farmacéuticas del mismo para tratar enfermedades o trastornos mediados por un antígeno tumoral, y el uso del anticuerpo biespecífico según la invención y otros compuestos terapéuticamente activos para tratar enfermedades o trastornos mediados por un antígeno tumoral.</p>
CU2025000022A 2023-03-10 2024-03-07 Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral CU20250022A7 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2023105614A RU2023105614A (ru) 2023-03-10 Выделенное биспецифическое антитело, которое специфически связывается с CD3 и опухолевым антигеном, и его применение
PCT/RU2024/050053 WO2024191322A1 (en) 2023-03-10 2024-03-07 Isolated bispecific antibody that specifically binds to cd3 and tumor antigen, and use thereof

Publications (1)

Publication Number Publication Date
CU20250022A7 true CU20250022A7 (es) 2026-04-09

Family

ID=92756228

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2025000022A CU20250022A7 (es) 2023-03-10 2024-03-07 Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral

Country Status (19)

Country Link
EP (1) EP4676972A1 (es)
JP (1) JP2026507937A (es)
KR (1) KR20250155062A (es)
CN (1) CN120858118A (es)
AR (1) AR132099A1 (es)
AU (1) AU2024237201A1 (es)
CL (1) CL2025002740A1 (es)
CO (1) CO2025012267A2 (es)
CU (1) CU20250022A7 (es)
DO (1) DOP2025000224A (es)
GE (1) GEAP202616846A (es)
IL (1) IL323119A (es)
JO (1) JOP20250228A1 (es)
MX (1) MX2025010576A (es)
PE (1) PE20260009A1 (es)
PY (1) PY2418291A (es)
TW (1) TW202440632A (es)
UY (1) UY40668A (es)
WO (1) WO2024191322A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI701042B (zh) * 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
JP7267914B2 (ja) * 2016-11-02 2023-05-02 エンクマフ エスアーエールエル Ｂｃｍａ及びｃｄ３に対する二重特異性抗体、及び多発性骨髄腫を治療するために併用して使用される免疫療法薬

Also Published As

Publication number Publication date
JP2026507937A (ja) 2026-03-06
PE20260009A1 (es) 2026-01-06
KR20250155062A (ko) 2025-10-29
PY2418291A (es) 2024-11-12
CL2025002740A1 (es) 2025-12-12
GEAP202616846A (en) 2026-01-12
AR132099A1 (es) 2025-05-28
DOP2025000224A (es) 2025-11-16
AU2024237201A1 (en) 2025-09-18
IL323119A (en) 2025-11-01
CN120858118A (zh) 2025-10-28
TW202440632A (zh) 2024-10-16
WO2024191322A1 (en) 2024-09-19
JOP20250228A1 (ar) 2025-09-09
MX2025010576A (es) 2025-11-03
UY40668A (es) 2024-10-15
EP4676972A1 (en) 2026-01-14
CO2025012267A2 (es) 2026-01-23

Similar Documents

Publication Publication Date Title
PY24114686A (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente al ligando 1A (TL1A) similar al TNF, y uso del mismo
CU20250022A7 (es) Anticuerpo biespecífico que se une específicamente al cd3 y al antígeno tumoral
AR127635A1 (es) ANTICUERPO MONOCLONAL O FRAGMENTO DE UNIÓN A UN ANTÍGENO QUE SE UNE ESPECÍFICAMENTE A LA IL-4Ra, Y USO DEL MISMO
CL2023003854A1 (es) Anticuerpo biespecífico aislado que se une específicamente a cd47 y pd-l1
AR132867A1 (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a axl, y uso del mismo
CR20240559A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente a bcma, y uso del mismo
CR20230456A (es) Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo
PY2530271A (es) Anticuerpo monoclonal o fragmento de unión a antígeno del mismo que se une específicamente a bdca-2, y uso del mismo
AR132062A1 (es) Anticuerpos multiespecíficos anti-cd3 y métodos de uso
AR132063A1 (es) Anticuerpos multiespecíficos anti-cldn6 y anti-cd3 y métodos de uso